Sign In
Buy CODX
Company-Diagnostics Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$3.75 |
| EPS actual | -$4.06 |
| EPS Surprise | -8.27% |
| Revenue estimate | 127.052K |
| Revenue actual | 145.954K |
| Revenue Surprise | 14.88% |
| Release date | Mar 31, 2026 |
| EPS estimate | -$3.60 |
| EPS actual | -$16.35 |
| EPS Surprise | -354.17% |
| Revenue estimate | 125.883K |
| Revenue actual | 262.489K |
| Revenue Surprise | 108.52% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$5.71 |
| EPS actual | -$4.80 |
| EPS Surprise | 15.94% |
| Revenue estimate | 126K |
| Revenue actual | 145.38K |
| Revenue Surprise | 15.38% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.250 |
| EPS actual | -$0.230 |
| EPS Surprise | 8.00% |
| Revenue estimate | 300K |
| Revenue actual | 162.91K |
| Revenue Surprise | -45.70% |
Last 4 Quarters for Company-Diagnostics
Below you can see how CODX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $0.265 |
| EPS estimate | -$0.250 |
| EPS actual | -$0.230 |
| EPS surprise | 8.00% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $0.254 |
| Aug 11, 2025 | $0.253 |
| Aug 12, 2025 | $0.254 |
| Aug 13, 2025 | $0.263 |
| Aug 14, 2025 | $0.265 |
| Aug 15, 2025 | $0.294 |
| Aug 18, 2025 | $0.320 |
| Aug 19, 2025 | $0.290 |
| Aug 20, 2025 | $0.282 |
| 4 days before | 4.36% |
| 4 days after | 6.18% |
| On release day | 10.85% |
| Change in period | 10.81% |
| Release date | Nov 13, 2025 |
| Price on release | $0.372 |
| EPS estimate | -$5.71 |
| EPS actual | -$4.80 |
| EPS surprise | 15.94% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $0.406 |
| Nov 10, 2025 | $0.390 |
| Nov 11, 2025 | $0.394 |
| Nov 12, 2025 | $0.396 |
| Nov 13, 2025 | $0.372 |
| Nov 14, 2025 | $0.331 |
| Nov 17, 2025 | $0.316 |
| Nov 18, 2025 | $0.359 |
| Nov 19, 2025 | $0.342 |
| 4 days before | -8.40% |
| 4 days after | -7.98% |
| On release day | -10.94% |
| Change in period | -15.71% |
| Release date | Mar 31, 2026 |
| Price on release | $1.86 |
| EPS estimate | -$3.60 |
| EPS actual | -$16.35 |
| EPS surprise | -354.17% |
| Date | Price |
|---|---|
| Mar 25, 2026 | $1.97 |
| Mar 26, 2026 | $2.02 |
| Mar 27, 2026 | $1.75 |
| Mar 30, 2026 | $1.70 |
| Mar 31, 2026 | $1.86 |
| Apr 01, 2026 | $1.62 |
| Apr 02, 2026 | $1.54 |
| Apr 06, 2026 | $1.54 |
| Apr 07, 2026 | $1.42 |
| 4 days before | -5.58% |
| 4 days after | -23.66% |
| On release day | -12.90% |
| Change in period | -27.92% |
| Release date | May 14, 2026 |
| Price on release | $1.63 |
| EPS estimate | -$3.75 |
| EPS actual | -$4.06 |
| EPS surprise | -8.27% |
| Date | Price |
|---|---|
| May 08, 2026 | $2.53 |
| May 11, 2026 | $1.90 |
| May 12, 2026 | $1.72 |
| May 13, 2026 | $1.60 |
| May 14, 2026 | $1.63 |
| May 15, 2026 | $1.29 |
| May 18, 2026 | $1.37 |
| May 19, 2026 | $1.97 |
| May 20, 2026 | $2.39 |
| 4 days before | -35.57% |
| 4 days after | 46.63% |
| On release day | -21.17% |
| Change in period | -5.53% |
Company-Diagnostics Earnings Call Transcript Summary of Q1 2026
Co-Diagnostics (Q1 2026): Management emphasized progress toward commercialization across multiple fronts. The company completed enrollment (~1,400 patients) in its upper respiratory multiplex clinical study (originally designed to detect Flu A, Flu B, COVID-19 and RSV) and plans an initial 510(k) submission focused on Flu A, Flu B and RSV with a target to file in Q3 2026 for CLIA-waived point-of-care clearance, subject to final validation and regulatory review. India remains a strategic priority through the CoSara joint venture: CoSara received a CDSCO manufacturing license for the PCR Pro instrument, will locally manufacture instruments and consumables, has expanded its South Asia territory (total addressable market ~ $13 billion), and Co-Dx is evaluating strategic alternatives (including a potential SPAC) to capitalize CoSara. TB clinical performance studies in India are scheduled to begin shortly, with commercialization in India potentially by end of Q3; company highlights alignment with new WHO guidance and Gates Foundation–supported design. The CoMira JV in Saudi Arabia advanced (industrial land allocation in Sudair, facility lease progress, initial funding contributions completed) as part of a localization strategy to serve the MENA region. Technology initiatives include cloud connectivity, ML/algorithm capabilities, and planned automation of test-cup manufacturing (target ~4x efficiency improvement). Financials: Q1 revenue was $0.146M (vs. $0.05M Y/Y); gross loss of $0.048M; operating expenses $9.2M (R&D $5.9M); net loss $9.1M (–$4.06/share) vs. $7.5M prior year. Cash was $8.2M at quarter-end (vs. $11.9M FY2025); management expects continued operating losses and that additional capital will likely be required, while evaluating equity, debt, strategic partnerships and nondilutive grants. Overall, the company is positioning for key regulatory and commercialization inflection points (510(k) submission, TB clinical start, local manufacturing ramp) while acknowledging limited near-term revenue and the need for further financing.
